Bio-Techne Corp Stock Price, News & Analysis

Bio-Techne (NASDAQ: TECH) has announced a strategic partnership with Spear Bio to distribute next-generation ultrasensitive immunoassays for neurodegenerative disease research. The partnership follows Bio-Techne's participation in Spear Bio's $45 million Series A funding in 2024.

The collaboration will focus on distributing Spear Bio's SPEAR platform technology, which offers 2-3 orders of magnitude higher sensitivity than current immunoassay platforms. The initial offering targets key Alzheimer's disease biomarkers including pTau 217, GFAP, Nf-L, and pTau 231.

This partnership leverages Bio-Techne's global distribution network and immunoassay expertise with Spear Bio's ultrasensitive technology to advance early disease detection and therapeutic development.

Bio-Techne (NASDAQ: TECH) announced that its Simple Western™ Technology was instrumental in supporting the FDA approval of ZEVASKYN™, the first autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB), developed by Abeona Therapeutics.

The Simple Western platform was chosen for its superior capabilities in detecting and quantifying Collagen VII, a critical protein for ZEVASKYN's potency testing. The technology's advantages include picogram-level sensitivity, reproducibility, and minimal sample requirements, making it essential for GMP-compliant lot release testing of both viral vector and cell therapy components.

The platform successfully overcame complex analytical challenges in standardization and assay development, particularly in evaluating Collagen VII's tertiary structure under non-denaturing conditions.

Bio-Techne (NASDAQ: TECH) has announced a strategic distribution agreement with the U.S. Pharmacopeia (USP) to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards alongside its analytical solutions, including the Maurice system.

The collaboration aims to support the development of monoclonal antibody and gene therapy products worldwide. With over 160 approved antibody therapies globally, the partnership addresses critical quality control needs in both mAb development and the rapidly growing gene therapy sector. The integration of USP reference standards with Bio-Techne's analytical instruments will enable therapy manufacturers to achieve reliable characterization for purity, charge, size, and identity applications throughout product development.

ScaleReady has awarded a $150,000 G-Rex Grant to Immuneel Therapeutics to enhance CAR-T cell manufacturing in India. The grant aims to support process development for improving scalability and cost-effectiveness of production at Immuneel's 12,000 square foot GMP facility in Bengaluru. With India facing approximately 120,000 new blood cancer cases annually and 70,000 related deaths, Immuneel targets manufacturing nearly 200 drug products daily. The G-Rex Grant Program, which has increased from $20M to $30M in total funding, has awarded 200 grants with over 50 applications pending. Recipients can receive up to $300,000 and access support from ScaleReady's consortium of partners specializing in cGMP manufacturing, quality control, and CGT business operations.

Bio-Techne Corporation (NASDAQ: TECH) has announced its participation in three major upcoming investor conferences in June 2025. The company will present at the William Blair 45th Annual Growth Stock Conference on June 3 at 2:40 PM CDT, the Jefferies Global Healthcare Conference on June 4 at 3:45 PM EDT, and the Goldman Sachs 46th Annual Global Healthcare Conference on June 10 at 10:40 AM EDT. Investors can access live webcasts of all presentations through Bio-Techne's Investor Relations website.

ScaleReady has awarded $1,025,000 in G-Rex Grants to researchers at USC and Children's Hospital of Los Angeles (CHLA) to advance cell and gene therapy initiatives. The grants were distributed among four recipients: Dr. Mohamed Abou-el-Enein ($300,000) for CAR-T cell therapies manufacturing platform, Dr. Saul Priceman ($275,000) for solid cancer treatment research, Dr. Shahab Asgharzadeh ($250,000) for pediatric solid tumor therapy development, and Dr. Preet Chaudhary ($200,000) for solid tumor treatment research. The G-Rex Grant Program has made nearly 200 awards to date and has been extended with additional funding. Recipients gain access to ScaleReady's consortium of partners providing expertise in cGMP manufacturing, quality control, and regulatory affairs.

Bio-Techne (NASDAQ: TECH) will showcase its latest innovations at the American Society of Gene & Cell Therapy (ASGCT) 2025 meeting in New Orleans from May 13-17. Key highlights include the new RNAscope™ protease-free workflow for AAV vector visualization, ProPak™ GMP cytokines in dose-optimized bags, and the next-generation Simple Western Leo™ System capable of processing 100 samples in 3 hours.

The company will host a symposium on May 14th featuring presentations from industry leaders, including speakers from Dyno Therapeutics and Tessera Therapeutics. An additional talk on protein quantitation applications will be held on May 15th with speakers from Sangamo Therapeutics and Nervosave Therapeutics.

Bio-Techne (NASDAQ: TECH) and Kytopen have announced a partnership to enhance cell therapy manufacturing through integrated cellular engineering workflow. The collaboration combines Bio-Techne's TcBuster™ GMP non-viral genome engineering system with Kytopen's Flowfect Tx™ GMP cellular engineering platform.

The TcBuster™ system enables simultaneous delivery of multiple genes with high editing efficiency in a single vector, while Flowfect® technology processes billions of cells in minutes using a combination of mechanical, electrical, and chemical forces. Together, these technologies aim to streamline gene delivery processes and accelerate the development of advanced cell therapies.

The companies will present their collaborative data at the International Society of Cell & Gene Therapy (ISCT) Annual Meeting in New Orleans, May 7-10, 2025.

Bio-Techne Corporation (NASDAQ: TECH) has announced that its President and CEO, Kim Kelderman, will present at the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 10:40 a.m. PDT. Investors and interested parties can access a live webcast of the presentation through Bio-Techne's Investor Relations website, specifically on the IR Calendar page.